東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Mathematical Models to Evaluate the ...

Adamson, Blythe.

FindBook

Google Book

Amazon

博客來

Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States./
作者:	Adamson, Blythe.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2018,
面頁冊數:	178 p.
附註:	Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
Contained By:	Dissertation Abstracts International79-12B(E).
標題:	Pharmaceutical sciences. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10747748
ISBN:	9780438173217

Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States.
Adamson, Blythe.

Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States. - Ann Arbor : ProQuest Dissertations & Theses, 2018 - 178 p.

Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.

Thesis (Ph.D.)--University of Washington, 2018.

As the marginal clinical impact returns on innovations to treat and prevent HIV diminish, strategic investments are required for timely and efficient HIV eradication. The overall goal of this dissertation research is to evaluate the potential cost-effectiveness of several pharmacotherapy-related interventions included in the National HIV/AIDS Strategy for the United States in order to inform decision-making and policy design. Rising HIV program costs along with poor results in patient access and service utilization make determining the value of new HIV interventions very important for the vulnerable populations bearing the disease burden. Today, pre-exposure prophylaxis (PrEP) drugs are a short-term solution. Quite soon, programs offering financial incentives for viral suppression are expected to expand. Over the long term, many view the development of a safe and effective HIV vaccine as the only hope to completely eradicate AIDS. I develop a series of mathematical models to examine the clinical and economic impact of financial incentives, PrEP, and HIV vaccines using local and national surveillance data drawing on the results of large clinical trials. Importantly, I examine the potential interaction and competition between PrEP and HIV vaccines which needs to be understood to achieve optimal benefit from the combined use of the two in the coming decades. Lastly, I make policy and R&D; investment recommendations aimed to support efficient progress towards the national strategic goals.

ISBN: 9780438173217Subjects--Topical Terms:

3173021
Pharmaceutical sciences.

Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States.
LDR:02532nmm a2200313 4500 001 2203719
005 20190606091702.5
008 201008s2018 ||||||||||||||||| ||eng d
020 $a 9780438173217
035 $a (MiAaPQ)AAI10747748
035 $a (MiAaPQ)washington:18258
035 $a AAI10747748
040 $a MiAaPQ $c MiAaPQ
100 1 $a Adamson, Blythe. $3 3430525
245 1 0 $a Mathematical Models to Evaluate the Clinical and Economic Impact of Biomedical HIV Prevention Strategies in the United States.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2018
300 $a 178 p.
500 $a Source: Dissertation Abstracts International, Volume: 79-12(E), Section: B.
500 $a Adviser: Louis Garrison.
502 $a Thesis (Ph.D.)--University of Washington, 2018.
520 $a As the marginal clinical impact returns on innovations to treat and prevent HIV diminish, strategic investments are required for timely and efficient HIV eradication. The overall goal of this dissertation research is to evaluate the potential cost-effectiveness of several pharmacotherapy-related interventions included in the National HIV/AIDS Strategy for the United States in order to inform decision-making and policy design. Rising HIV program costs along with poor results in patient access and service utilization make determining the value of new HIV interventions very important for the vulnerable populations bearing the disease burden. Today, pre-exposure prophylaxis (PrEP) drugs are a short-term solution. Quite soon, programs offering financial incentives for viral suppression are expected to expand. Over the long term, many view the development of a safe and effective HIV vaccine as the only hope to completely eradicate AIDS. I develop a series of mathematical models to examine the clinical and economic impact of financial incentives, PrEP, and HIV vaccines using local and national surveillance data drawing on the results of large clinical trials. Importantly, I examine the potential interaction and competition between PrEP and HIV vaccines which needs to be understood to achieve optimal benefit from the combined use of the two in the coming decades. Lastly, I make policy and R&D; investment recommendations aimed to support efficient progress towards the national strategic goals.
590 $a School code: 0250.
650 4 $a Pharmaceutical sciences. $3 3173021
650 4 $a Economics. $3 517137
650 4 $a Applied mathematics. $3 2122814
690 $a 0572
690 $a 0501
690 $a 0364
710 2 $a University of Washington. $b Pharmacy. $3 3186017
773 0 $t Dissertation Abstracts International $g 79-12B(E).
790 $a 0250
791 $a Ph.D.
792 $a 2018
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10747748